Literature DB >> 15970766

Benign essential blepharospasm.

Guy J Ben Simon1, John D McCann.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15970766     DOI： 10.1097/01.iio.0000167238.26526.a8

Source DB:  PubMed          Journal:  Int Ophthalmol Clin        ISSN： 0020-8167


× No keyword cloud information.
  8 in total

1.  Risk of glaucoma among patients with benign essential blepharospasm.

Authors:  Michael S Lee; Andrew R Harrison; Daniel S Grossman; Frank A Sloan
Journal:  Ophthalmic Plast Reconstr Surg       Date:  2010 Nov-Dec       Impact factor: 1.746

2.  Long-term follow-up of patients with frontalis sling operation in the treatment of essential blepharospasm unresponsive to botulinum toxin therapy.

Authors:  Bettina Wabbels; Peter Roggenkämper
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2006-07-28       Impact factor: 3.117

Review 3.  Botulinum toxin in the treatment of blepharospasm and hemifacial spasm.

Authors:  C Kenney; J Jankovic
Journal:  J Neural Transm (Vienna)       Date:  2007-06-11       Impact factor: 3.575

4.  Botulinum toxin in the management of dystonia.

Authors:  Omar D Cardona-Garcia; Donald S Higgins; Eric S Molho
Journal:  Curr Treat Options Neurol       Date:  2007-05       Impact factor: 3.598

5.  Evaluation of Intraocular Pressure After Water Drinking Test in Patients with Unilateral Hemifacial Spasm.

Authors:  Jin Rong Low; Chee Wai Wong; Jing Liang Loo; Dan Milea; Shamira A Perera; Yi Fang Lee; Si Rui Ng; Mani Baskaran; Monisha Esther Nongpiur; Sharon Lee Choon Tow
Journal:  Clin Ophthalmol       Date:  2020-06-18

6.  SURGICAL ASPECT OF BLEPHAROSPASM TREATMENT: A CASE REPORT.

Authors:  Kristijan Dinjar; Vedran Zubčić; Andrijana Kopić; Vlatko Kopić; Bruno Popić; Dubravka Holik
Journal:  Acta Clin Croat       Date:  2020-06       Impact factor: 0.780

7.  Ultra-Long-Term Therapy of Benign Essential Blepharospasm with Botulinumtoxin A-30 Years of Experience in a Tertiary Care Center.

Authors:  Bettina Wabbels; Rolf Fimmers; Peter Roggenkämper
Journal:  Toxins (Basel)       Date:  2022-02-07       Impact factor: 4.546

8.  Neurologic uses of botulinum neurotoxin type A.

Authors:  John P Ney; Kevin R Joseph
Journal:  Neuropsychiatr Dis Treat       Date:  2007-12       Impact factor: 2.570
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.